RCS - Immupharma PLC - IMM TO PRESENT AT BIOTECH SHOWCASE DIGITAL 2021

ImmuPharmaAnnouncement

02/12/2020 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201202:nRSB1444Ha&default-theme=true

RNS Number : 1444H  Immupharma PLC  02 December 2020

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

IMMUPHARMA TO PRESENT AT BIOTECH SHOWCASE™ DIGITAL 2021

11-15 January 2021

 

ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company,
announces that Dr Tim Franklin, ImmuPharma's Chief Operating Officer, will be
presenting at the prestigious Biotech Showcase™ Digital 2021. The event will
be virtually held between 11 and 15 January 2021.

 

As part of ImmuPharma's participation, an on-demand Company presentation has
been provided in advance to the opening of the event. This will allow
registered attendees to get access to presentation material prior to the start
of the showcase on 11 January 2021.

 

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor
conference focused on driving advances in therapeutic development by providing
a sophisticated networking platform for executives and investors that fosters
investment and partnership opportunities. The conference takes place each year
during the course of one of the industry's largest gatherings and busiest
weeks.

 

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )  + 44 (0) 207 152 4080

 Tim McCarthy, Chairman
 Dimitri Dimitriou, Chief Executive Officer
 Lisa Baderoon, Head of Investor Relations                         + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                           +44 (0) 203 368 3550 (about:blank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                          +44 (0) 203 815 8880

 Patrick Claridge

 John Howes

 Bob Pountney                                                      +44 (0) 1483 413500

 SI Capital (Joint Broker)

 Nick Emerson

 4Reliance (Euronext Growth Listing Sponsor)                       +32 (0) 2 747 02 60

 Jean-Charles Snoy

 Degroof Petercam (Liquidity Provider)                             +32 (0) 2 287 95 34

 Erik De Clippel

 Backstage Communication

 Olivier Duquaine                                                  +32 (0) 477 504 784

 Gunther De Backer                                                 +32 (0) 475 903 909

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty
biopharmaceutical company that discovers and develops peptide-based
therapeutics. The Company's portfolio includes novel peptide therapeutics for
autoimmune diseases, anti-infectives, metabolic diseases and cancer. The lead
program, Lupuzor™, is a first-in class autophagy immunomodulator which is in
Phase III for the treatment of systemic lupus erythematosus (lupus / SLE).
Lupus is an autoimmune disease which if left untreated can be fatal.
Preclinical analysis suggest therapeutic activity for many other autoimmune
diseases that share the same autophagy mechanism of action. ImmuPharma and
Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and
development agreement and trademark agreement for Lupuzor™ to fund a new
international Phase III trial for Lupuzor™ and commercialise in the US.

 

For additional information about ImmuPharma please visit www.immupharma.com
(http://www.immupharma.com) .

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

About Biotech Showcase

 

Biotech Showcase is an investor and networking conference devoted to providing
private and public biotechnology and life sciences companies with an
opportunity to present to, and meet with, investors and pharmaceutical
executives in one place. Investors and biopharmaceutical executives from
around the world gather in San Francisco during this bellwether week which
sets the tone for the coming year. Now in its 13th year, this
well-established, highly respected conference features multiple tracks of
presenting companies, plenary sessions, workshops, networking, and an
opportunity to schedule one-to-one meetings. Biotech Showcase is produced by
Demy-Colton and EBD Group. Both organizations have a long history of producing
high-quality programs that support the biotechnology and broader life sciences
industry.

 

About Reach announcements

Reach is an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute media only /
non-regulatory news releases such as marketing messages, corporate and product
information into the public domain. An RNS Regulatory announcement is required
to be notified under the AIM Rules for Companies.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUASORRKUURAA